| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2025 ended Dec 31, 2024 | FY 2025 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 6.72B | 6.34B | 5.96B | 6.96B | 7.73B | 6.38B |
| Depreciation and amortization | 1.05B | 1.16B | 1.07B | 986.00M | 831.00M | 658.00M |
| Stock-based compensation | 310.00M | 301.00M | 278.00M | 307.00M | 230.00M | 196.00M |
| Cash from operations | 7.82B | 8.67B | 8.41B | 9.15B | 9.31B | 8.29B |
| Capital expenditure | -1.52B | -1.40B | -1.48B | -2.24B | -2.52B | -1.47B |
| Free cash flow | 6.29B | 7.27B | 6.93B | 6.91B | 6.79B | 6.82B |
| Acquisitions | -4.04B | -3.13B | -3.66B | -39.00M | -19.39B | -38.00M |
| Cash from investing | -4.05B | -5.84B | -5.14B | -2.16B | -21.93B | -1.51B |
| Dividends paid | -636.00M | -583.00M | -523.00M | -455.00M | -395.00M | -337.00M |
| Share buybacks | -3.00B | -4.00B | -3.00B | -3.00B | -2.00B | -1.50B |
| Net debt issued | 5.35B | -2.40B | 160.00M | 2.82B | 6.40B | 2.75B |
| Cash from financing | 1.80B | -6.79B | -3.62B | -2.81B | 6.58B | 959.00M |
| Net change in cash | 5.84B | -4.06B | -440.00M | 4.05B | -5.84B | 7.91B |
From Thermo Fisher Scientific's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.